Related Experiment Video
Updated: Sep 16, 2025
09:26
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
16.8K
Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma
Kate Byrne1,2, Natalia Bednarz1,2, Ciara McEvoy1,3
1School of Food Science and Environmental Health, Technological University Dublin, Grangegorman Lower, Dublin 7, Dublin, D07 ADY7, Ireland.
Chemmedchem
|July 8, 2025
Summary
Researchers identified novel pyrazolo[1,5-α]pyrimidinones as potential glioblastoma (GBM) cancer treatments. These compounds show selective cytotoxicity against GBM cells, offering a promising new avenue for brain cancer therapy.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and high resistance to chemotherapy.
- Pyrazolo[1,5-α]pyrimidinones are heterocyclic scaffolds found in various bioactive molecules.
Purpose of the Study:
- To investigate the potential of pyrazolo[1,5-α]pyrimidinones derivatives as selective anti-glioblastoma agents.
- To conduct a structure-activity relationship (SAR) study to identify lead compounds.
Main Methods:
- Screening of 23 substituted pyrazolo[1,5-α]pyrimidinones for cytotoxicity against GBM U-251 MG and HEK293 cell lines.
- Analog synthesis to optimize preliminary hit compounds.
- Investigation of cell death mechanisms.
Main Results:
- A lead compound, 22, demonstrated significant GBM cell death with marginal cytotoxicity to noncancerous cells.
- Identified compounds induced cell death via mechanisms including membrane permeabilization and mitochondrial depolarization.
- Selective cytotoxicity against cancer cells was observed.
Conclusions:
- Pyrazolo[1,5-α]pyrimidinones derivatives show promise as a novel therapeutic strategy for glioblastoma.
- The scaffold is suitable for developing selective GBM therapies.
- Further development could lead to new anti-cancer drugs.
